Mucosis BV has signed a research and license option agreement with Crucell Holland B.V., under which Crucell will use Mucosis' Mimopath platform technology to develop vaccines for infectious diseases. Mucosis will receive upfront payments and is eligible to receive achievement-based milestones. Financial terms were not disclosed.
"We are delighted to collaborate with Crucell as we strongly believe that our Mimopath platform combined with Crucell's expertise in vaccine development create a substantial opportunity to develop differentiated and medically relevant vaccine candidates," said Thomas Johnston, chief executive officer of Mucosis. "We are proud of the progress we've made to date in developing the Mimopath platform, including our recent positive human clinical trials. We see this agreement as a further validation of our platform and its potential to combat infectious diseases."